Clinical features and response data for C&Ckine signatures based on bimodal C&Ckines
| Category . | B1 . | B2 . | B3 . | B4 . | B5 . | B6 . | B7 . | B8 . | B9 . |
|---|---|---|---|---|---|---|---|---|---|
| All cases | |||||||||
| AML | 21 | 38 | 20 | 38 | 11 | 8 | 9 | 15 | 2 |
| MDS | 23 | 18 | 14 | 20 | 4 | 8 | 13 | 0 | 1 |
| Normal | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 19 |
| B1 | B2 | B3 | B4 | B5 | B6 | B7 | B8 | Total | |
| New AML | |||||||||
| No. | 17 | 19 | 16 | 31 | 10 | 7 | 8 | 14 | 122 |
| AHD/secondary AML | 23.5% | 47.4% | 43.8% | 35.5% | 50.0% | 42.9% | 37.5% | 50.0% | 40.2% |
| Favorable cytogenetics | 5.9% | 0.0% | 18.8% | 9.7% | 0.0% | 0.0% | 0.0% | 0.0% | 5.7% |
| Intermediate cytogenetics | 41.2% | 52.6% | 25.0% | 51.6% | 50.0% | 71.4% | 62.5% | 21.4% | 45.1% |
| Unfavorable cytogenetics | 52.9% | 47.4% | 56.3% | 38.7% | 50.0% | 28.6% | 37.5% | 78.6% | 49.2% |
| FLT3 mutation | 25.0% | 15.4% | 0.0% | 12.5% | 28.3% | 50.0% | 33.0% | 22.0% | 18.8% |
| Treated new AML | |||||||||
| Treated | 17 | 18 | 16 | 28 | 10 | 6 | 7 | 12 | 114 |
| CR | 76.5% | 33.3% | 68.8% | 71.4% | 50.0% | 50.0% | 28.6% | 58.3% | 58.8% |
| Resistant | 23.5% | 38.9% | 25.0% | 25.0% | 20.0% | 50.0% | 71.4% | 25.0% | 30.7% |
| Fail | 0.0% | 27.8% | 6.3% | 3.6% | 30.0% | 0.0% | 0.0% | 16.7% | 10.5% |
| Relapse | 76.9% | 66.7% | 36.4% | 55.0% | 80.0% | 66.7% | 50.0% | 57.1% | 59.7% |
| Alive | 23.5% | 5.6% | 18.8% | 25.0% | 10.0% | 16.7% | 14.3% | 25.0% | 18.4% |
| Category . | B1 . | B2 . | B3 . | B4 . | B5 . | B6 . | B7 . | B8 . | B9 . |
|---|---|---|---|---|---|---|---|---|---|
| All cases | |||||||||
| AML | 21 | 38 | 20 | 38 | 11 | 8 | 9 | 15 | 2 |
| MDS | 23 | 18 | 14 | 20 | 4 | 8 | 13 | 0 | 1 |
| Normal | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 19 |
| B1 | B2 | B3 | B4 | B5 | B6 | B7 | B8 | Total | |
| New AML | |||||||||
| No. | 17 | 19 | 16 | 31 | 10 | 7 | 8 | 14 | 122 |
| AHD/secondary AML | 23.5% | 47.4% | 43.8% | 35.5% | 50.0% | 42.9% | 37.5% | 50.0% | 40.2% |
| Favorable cytogenetics | 5.9% | 0.0% | 18.8% | 9.7% | 0.0% | 0.0% | 0.0% | 0.0% | 5.7% |
| Intermediate cytogenetics | 41.2% | 52.6% | 25.0% | 51.6% | 50.0% | 71.4% | 62.5% | 21.4% | 45.1% |
| Unfavorable cytogenetics | 52.9% | 47.4% | 56.3% | 38.7% | 50.0% | 28.6% | 37.5% | 78.6% | 49.2% |
| FLT3 mutation | 25.0% | 15.4% | 0.0% | 12.5% | 28.3% | 50.0% | 33.0% | 22.0% | 18.8% |
| Treated new AML | |||||||||
| Treated | 17 | 18 | 16 | 28 | 10 | 6 | 7 | 12 | 114 |
| CR | 76.5% | 33.3% | 68.8% | 71.4% | 50.0% | 50.0% | 28.6% | 58.3% | 58.8% |
| Resistant | 23.5% | 38.9% | 25.0% | 25.0% | 20.0% | 50.0% | 71.4% | 25.0% | 30.7% |
| Fail | 0.0% | 27.8% | 6.3% | 3.6% | 30.0% | 0.0% | 0.0% | 16.7% | 10.5% |
| Relapse | 76.9% | 66.7% | 36.4% | 55.0% | 80.0% | 66.7% | 50.0% | 57.1% | 59.7% |
| Alive | 23.5% | 5.6% | 18.8% | 25.0% | 10.0% | 16.7% | 14.3% | 25.0% | 18.4% |
B1 through B8 indicates C&Ckine signature number based on bimodal analytes.
AHD/second indicates antecedent hematologic disorder ≥ 2 months or secondary AML; FLT3 mutation, positive test for an FLT-internal tandem duplication or D835 mutation; and CR, complete remission.